Premium Domain Names for Sale at
Chicago, IL – October 24, 2023 – Today, Zacks Investment Ideas feature highlights Fresenius Medical Care FMS, Vericel VCEL and ImmunoGen IMGN.
Recent volatility in the stock market has been fueled by the 10-Year Treasury Yield rising over the last few weeks and still hovering near 5%.
Fear may be settling in as Bearish pundits start to make their case. However, several Zacks Medical sector stocks were recently added to the Zacks Rank #1 (Strong Buy) list over the last week and should be viable options for investors during economic uncertainty as healthcare is always essential.
Fresenius Medical Care: Speaking to the essentiality of healthcare, Fresenius Medical Care's stock is starting to look attractive even with global economic fears still prevalent. Based in Germany, Fresenius is one of the largest integrated providers of dialysis products and services for chronic kidney failure.
Notably, fiscal 2023 and FY24 earnings estimates have remained higher over the last 60 days with Fresenius' stock trading attractively at 13.4X forward earnings. Annual earnings are forecasted to dip -21% in FY23 at $1.30 per share following a tough-to-compete-against year but rebound and soar 23% in FY24 to $1.60 a share.
Plus, sales are projected to be up 5% this year and rise another 3% in FY24 to $21.97 billion. Fresenius also offers a generous 2.35% annual dividend yield with shares of FMS still up a respectable +5% in 2023.
Vericel: Soaring +28% this year, Vericel Corporation's stock stands out and investors may be eager to buy VCEL shares on the dip. Focused on developing patient-specific expanded cell therapies used in the treatment of severe diseases/conditions, Vericel's top-line expansion largely points to its future earnings potential.
Catapulting Vericel's stock, sales are forecasted to jump 19% this year and climb another 24% in FY24 to $243.44 million. More intriguing, with earnings estimates on the rise the company is expecting a smaller adjusted loss of -$0.23 a share in FY23 with EPS forecasted to climb into the black at $0.08 per share in FY24.
ImmunoGen: Lastly, ImmunoGen's stock has skyrocketed +157% YTD and is a very enticing buy-the-dip candidate with IMGN shares trading at $12 and 38% from 52-week highs of $20 per share seen in July.
The very strong price performance in ImmunoGen stock has been attributed to a strengthening outlook as a biotechnology company focused on the development of targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology.
Annual earnings estimates have soared throughout the quarter with FY23 EPS anticipated at an adjusted loss of -$0.10 a share compared to -$0.88 per share last year. Fiscal 2024 earnings are now expected to leap into the black at $0.19 per share. Furthermore, sales are expected at $340.39 million this year compared to $108.78 million in 2022 with ImmunoGen's top line projected to expand another 45% in FY24 to $493.74 million.
Given the strengthening outlook of these healthcare stocks they currently have an "A" Zacks Style Scores grade for Momentum in addition to their Zacks Rank #1 (Strong Buy). The trend of rising earnings estimate revisions is compelling and makes Fresenius Medical Care, Vericel, and ImmunoGen's stock very attractive at the moment with the broader medical sector generally being an ideal place to hide out during market volatility.
Why Haven't You Looked at Zacks' Top Stocks?
Since 2000, our top stock-picking strategies have blown away the S&P's +6.2 average gain per year. Amazingly, they soared with average gains of +46.4%, +49.5% and +55.2% per year. Today you can access their live picks without cost or obligation.
See Stocks Free >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report
ImmunoGen, Inc. (IMGN) : Free Stock Analysis Report
Vericel Corporation (VCEL) : Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research
ImmunoGen (IMGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Japan's 10-year government bond yield touched a new decade-high on Wednesday on speculation that the Bank of Japan (BOJ) may raise its cap for the benchmark yield.
Solita Marcelli, chief investment officer for the Americas at UBS, reasons that gold's benefits as a safe haven remain intact.
Insider breaks down what you need to know about the bond-market meltdown, even if you've got no idea what a Treasury or a yield is.
The average of price targets set by Wall Street analysts indicates a potential upside of 43.9% in Nvidia (NVDA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Don't assume that all S&P 500 stocks are struggling. A small group are actually thriving, thank you.
Three of tech’s biggest names reported earnings Tuesday evening and the sector fell hard on Wednesday. While Microsoft surprised to the upside, Google’s cloud revenue came in below Wall Street estimates, sending that stock more than 9% lower by Wednesday afternoon. Chipmaker Texas Instruments’ latest outlook was bleak.
(Bloomberg) — Treasury yields surged Wednesday after poor demand for a sale of five-year notes deepened anxiety about auction size increases expected to be announced next week.Most Read from BloombergControversial Chip in Huawei Phone Produced on ASML MachineApple Plans AirPods Overhaul With New Low- and High-End Models, USB-C HeadphonesIsrael Is Losing Support as Fury Grows Over Its Strikes on GazaTrump Ally Mike Johnson Elected House Speaker, Shifting GOP Further RightPost-Earnings Meta Rally
The S&P 500 and Nasdaq rally attempts are over as Google dived. Meta reversed lower after hours with Amazon on tap.
High interest rates are derailing the ambitions of climate regulators and automakers to accelerate the shift to electric vehicles, underscored Wednesday by the scrapping of a GM-Honda partnership and a warning from a battery maker. Electric vehicle sales are still growing strongly, but that demand is not keeping up with the expectations of carmakers and other companies that have invested billions of dollars in the EV space. Expectations for persistently higher interest rates has led companies to alter plans as they eye 2024 warily.
(Bloomberg) — Looking for a unifying theory on what’s ailing equities in a world of vacillating bond yields, iffy earnings and mixed messages from the Federal Reserve? Try valuations.Most Read from BloombergControversial Chip in Huawei Phone Produced on ASML MachineApple Plans AirPods Overhaul With New Low- and High-End Models, USB-C HeadphonesIsrael Is Losing Support as Fury Grows Over Its Strikes on GazaTrump Ally Mike Johnson Elected House Speaker, Shifting GOP Further RightPost-Earnings Met
For the quarter ended Sept. 30, the parent of Facebook, Instagram, WhatsApp, and Threads reported revenue of $34.2 billion, up 23% and above the Wall Street consensus forecast at $33.5 billion. Meta shares have rallied 149% this year, driven largely by the company’s “year of efficiency” push to reduce costs and boost margins.
With China’s property bust threatening to sink the country’s economic recovery, Xi Jinping is looking for someone to blame. After putting the billionaire founder of Evergrande a heavily indebted property firm, under investigation for possible crimes, Beijing is expanding its probes to include bankers and financial institutions that facilitated developers’ risky behavior, people familiar with the matter say. Among those under scrutiny: a former head of Bank of China one of the country’s biggest lenders, the people said.
The three best CD rates available nationwide are 6.50% from Financial Partners Credit Union, 6.00% from Credit Human, and 5.80% from Seattle Bank.
A Wall Street analyst on Wednesday cut his price target on Apple stock amid reports of lackluster iPhone 15 sales.
Microsoft stock gained on a cloud revenue boost, Google's fell after a cloud miss. What are the expectations for AMZN stock?
Energy stocks with attractive portfolios are near buy points as the oil industry experiences some of the largest consolidations in more than two decades.
Legendary investor Warren Buffett has achieved astounding returns throughout his career. From 1964 to 2022, his company Berkshire Hathaway Inc. (NYSE:BRK) delivered an overall gain of 3,787,464%, dwarfing the S&P 500's 24,708% return during the same period. Other than picking stocks that skyrocketed in value, Buffett also collects dividends — a lot of dividends. Buffett famously said, "If you don't find a way to make money while you sleep, you will work until you die." Don't Miss: Elon Musk may
Treasury yields pushed higher, putting more pressure on already strained tech stocks.
Bill Gates, the seventh-richest person in the world according to the Forbes 2023 list, has been losing money on one of his latest investment bets. Gates, who amassed his wealth by cofounding and leading Microsoft Corp. for decades before retiring in 2008, has since focused on investing in private corporations and publicly traded companies. In the fiscal second quarter of 2023, Gates purchased over 1.7 million shares of Anheuser-Busch InBev (NYSE:BUD), maker of popular beer brands including Bud L

Premium Domain Names:

A premium domain name is a highly sought-after domain that is typically short, memorable, and contains popular keywords or phrases. These domain names are considered valuable due to their potential to attract more organic traffic and enhance branding efforts. Premium domain names are concise and usually consist of one to two words or two to four individual characters.

Top-Level Domain Names for Sale on

If you are looking for top-level domain names for sale, you can visit is a platform that offers a selection of domain names at various price ranges. It is important to note that the availability of specific domain names may vary, and it’s recommended to check the website for the most up-to-date information.

Contact at

If you have any inquiries or need assistance regarding the domain names available on, you can reach out to them via email at Feel free to contact them for any questions related to the domain names or the purchasing process.

Availability on,, and

Apart from, you can also explore other platforms like,, and for available domain names. These platforms are popular marketplaces for buying and selling domain names. Each platform may have its own inventory of domain names, so it’s worth checking multiple sources to find the perfect domain name for your needs.

#PremiumDomains #DomainInvesting #DigitalAssets #DomainMarketplace #DomainFlipping #BrandableDomains #DomainBrokers #DomainAcquisition #DomainPortfolio #DomainIndustry #DomainAuctions #DomainInvestors #DomainSales #DomainExperts #DomainValue #DomainBuyers #DomainNamesForSale #DomainBrand #DomainInvestment #DomainTrading

Leave a comment